Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 8/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713139 | 0.93 | PTGER4 (0.40) | PTGER4AGTR2AGTR1NR1H2NR1H3 | |
| SCHEMBL6018506 | 0.91 | PTGER4 (0.52) | PTGER4AGTR2AGTR1TP53KMT2A | |
| SCHEMBL21470296 | 0.89 | AGTR2 (0.38) | PTGER4AGTR2AGTR1 | |
| SCHEMBL21470225 | 0.89 | PTGER4 (0.37) | PTGER4AGTR2AGTR1TP53KMT2A | |
| SCHEMBL21470222 | 0.89 | PTGER4 (0.39) | PTGER4AGTR2AGTR1TP53KMT2A | |
| SCHEMBL30114869 | 0.89 | PTGER4 (0.37) | PTGER4AGTR2AGTR1TP53KMT2A | |
| SCHEMBL30115000 | 0.89 | AGTR2 (0.38) | PTGER4AGTR2AGTR1 | |
| SCHEMBL30114766 | 0.89 | PTGER4 (0.39) | PTGER4AGTR2AGTR1TP53KMT2A | |
| SCHEMBL1626050 | 0.89 | AGTR2 (0.39) | PTGER4AGTR2AGTR1KMT2ANR1H2 | |
| SCHEMBL2351543 | 0.88 | AGTR2 (0.43) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160317514-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2016-11-03 | — | — | US | claimed |
| EP-2976105-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | AskAt Inc. (JP) | 2016-01-27 | — | — | EP | claimed |
| WO-2014148053-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2014-09-25 | — | — | WO | claimed |
| EP-2538978-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RaQualia Pharma Inc (JP) | 2013-01-02 | — | — | EP | claimed |
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2012-12-13 | — | — | US | claimed |
| CN-102770159-A | Use of EP-4 receptor antagonists for the treatment of IL-23 mediated diseases | RAQUALIA PHARMA INC | 2012-11-07 | — | — | CN | claimed |
| WO-2011102149-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2011-08-25 | — | — | WO | claimed |
| US-20240066040-A1 | EP4 INHIBITORS AND USE THEREOF | ARRYS THERAPEUTICS INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240066040-A1 | EP4 INHIBITORS AND USE THEREOF | ARRYS THERAPEUTICS INC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-2976105-B1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC (JP) | 2023-01-04 | — | — | EP | disclosed |
| US-20210290641-A1 | EP4 INHIBITORS AND USE THEREOF | ASKAT INC. (JP) | 2021-09-23 | — | — | US | disclosed |
| US-10973834-B2 | EP4 inhibitors and use thereof | Arrys Therapeutics, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10786490-B2 | Use of EP4 receptor antagonists in the treatment of cartilage disease | ASKAT INC. (JP) | 2020-09-29 | — | — | US | disclosed |
| WO-2014148053-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2014-09-25 | — | — | WO | disclosed |
| EP-2538978-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RaQualia Pharma Inc (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2012-12-13 | — | — | US | disclosed |
| CN-102770159-A | Use of EP-4 receptor antagonists for the treatment of IL-23 mediated diseases | RAQUALIA PHARMA INC | 2012-11-07 | — | — | CN | disclosed |
| WO-2011102149-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2011-08-25 | — | — | WO | disclosed |
| US-6710054-B2 | CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290641-A1 | EP4 INHIBITORS AND USE THEREOF | PTGER4, EPB41, PTGER1 | PTGER4 1/4885AGTR2 3313/4885AGTR1 3509/4885 |
| US-10786490-B2 | Use of EP4 receptor antagonists in the treatment of cartilage disease | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885AGTR2 92/4885AGTR1 128/4885 |
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | PTGER4, PTGER3, IL23R | PTGER4 1/4885AGTR2 71/4885AGTR1 98/4885 |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | PTGER4 51/4885AGTR2 536/4885AGTR1 541/4885 |
| US-20160317514-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885AGTR2 94/4885AGTR1 136/4885 |
| US-10973834-B2 | EP4 inhibitors and use thereof | PTGER4, EPB41, PTGER1 | PTGER4 1/4885AGTR2 3313/4885AGTR1 3509/4885 |
| US-20240066040-A1 | EP4 INHIBITORS AND USE THEREOF | PTGER4, EPB41, PTGER1 | PTGER4 1/4885AGTR2 3313/4885AGTR1 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.